ADMA Biologics, Inc. forecasts EPS to quadruple by 2030, driven by strong revenue and margin growth. Click for this updated ...
California-based Palisades Investment Partners sold 398,647 shares of ADMA Biologics for an estimated $7.3 million in the third quarter. The transaction marked a full exit from ADMA, with Palisades ...
Investors in ADMA Biologics, Inc. ADMA need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 21, 2025 $5 Put had some of the highest implied ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback